Reports of myocarditis and pericarditis after COVID-19 vaccination: Communiqué to health practitioners

In May 2021, international reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines emerged, including from Israel and the United States. Follow-up on these cases is ongoing. No clear association has been established between myocarditis/pericarditis and mRNA vaccines, and to date, no regulatory action has been taken in Canada or internationally.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 17:24 (TU)
Créé le avril 17, 2026, 17:24 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-06-14 00:00:00
open_canada_keywords {"fr": ["En mai 2021", "des rapports internationaux", "inflammation du muscle cardiaque", "inflammation de la paroi", "autour du cœur", "après l'administration", "du vaccin à ARNm", "contre la COVID-19", "apparus", "notamment en Israël", "aux États-Unis", "Aucune association", "aucune mesure réglementaire", "prise au Canada", "ou à l'étranger", "Situation au Canada", "Rapports de myocardite", "péricardite", "après l’administration", "vaccin contre la COVID-19", "Communiqué", "aux professionnels de la santé", "myocardite", "péricardite", "Vaccin contre le COVID-19", "vaccination", "COVID-19", "professionnels de la santé", "ARNm", "Dans le cadre des efforts", "continus déployés", "pour assurer l'innocuité du vaccin", "contre la COVID-19", "l'Agence de la santé publique du Canada", "ASPC", "SC", "Santé Canada", "surveille de près", "la myocardite et la péricardite", "dans les systèmes canadien", "de surveillance passive et active", "de l'innocuité", "dont le Système canadien", "de surveillance des effets secondaires", "suivant l'immunisation", "SCSESSI", "le Programme Canada Vigilance", "CV", "le Canadian National", "Vaccine Safety Network", "CANVAS", "le Programme canadien de surveillance", "active de l'immunisation", "(IMPACT)", "SRAS-CoV-2", "coronavirus", "COVID", "IMPACT"], "en": ["Situation au Canada", "Reports of myocarditis", "pericarditis", "after COVID-19 vaccination", "Communiqué", "to health practitioners", "myocarditis", "pericarditis", "COVID-19 vaccination", "vaccination", "COVID-19", "health practitioners", "mRNA", "COVID-19 vaccine", "safety efforts", "PHAC", "Public Health Agency of Canada", "Health Canada", "HC", "monitoring myocarditis", "pericarditis", "in passive and active", "Canadian safety", "surveillance systems", "Canadian Adverse Events", "Immunization Surveillance System", "CAEFISS", "Canada Vigilance Program", "CV", "Canadian National", "Vaccine Safety Network", "CANVAS", "Canadian Immunization", "Monitoring Program ACTive", "(IMPACT)", "SRAS-CoV-2", "coronavirus", "COVID", "IMPACT", "inflammation of the heart muscle", "inflammation", "lining around the heart", "following vaccination", "with COVID-19", "mRNA vaccines emerged", "including from Israel", "no regulatory action", "in Canada", "internationally", "may 2021"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Rapports de myocardite ou péricardite après l’administration du vaccin contre la COVID-19 : Communiqué aux professionnels de la santé
update_frequency unknown